India approves human trials for second COVID-19 vaccine candidate

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 57 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 66%

Singapore Headlines News

Singapore Latest News,Singapore Headlines

Zydus has received approval from Indian regulators to begin human studies for its COVID-19 vaccine contender, the drugmaker said on Friday, as the ...

A healthcare worker checks the temperature of a resident during a medical campaign for COVID-19 at a slum area in Mumbai, India, Jun 30, 2020. BENGALURU: Zydus has received approval from Indian regulators to begin human studies for its COVID-19 vaccine contender, the drugmaker said on Friday , as the novel coronavirus infections continue to surge in the world's fourth worst-hit nation.

The potential vaccine showed a"strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus, part of Cadila Healthcare, said in a statement to Indian stock exchanges.India's approval for Zydus comes days after privately held Bharat Biotech got a similar green light for human studies for its vaccine candidate.Zydus will begin human trials this month in over 1,000 subjects in multiple sites in India, it said.

There were no safety concerns for the vaccine candidate in repeat dose toxicology studies, Zydus said. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic.No vaccine has yet been approved for commercial use against COVID-19, but more than a dozen from over 100 candidates globally are currently being tested in humans, and some have shown potential in early-stage trials.

The number of coronavirus infections in India surpassed 600,000 on Thursday, resulting in 17,834 deaths as authorities battled to contain the pandemic while easing lockdown rules.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in SG

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Golf: Olesen's European Tour ban lifted after Covid-19 delays trialLONDON (REUTERS) - Thorbjorn Olesen's ban has been lifted by the European Tour after his trial for misconduct was postponed due to the Covid-19 pandemic, the tour's governing body said on Thursday (July 2).. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

GE2020: COVID-19 patients, quarantined cannot vote; special voting hour for those on stay-home noticeSINGAPORE: COVID-19 patients and those in quarantine will not be able to vote in the 2020 General Election, but there will be a special voting ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

2 men charged with forging retrenchment letters to get COVID-19 support grantsSINGAPORE: Two men were charged in court on Wednesday (Jul 1) with forging retrenchment letters to obtain COVID-19 support grants, with one man ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacityBEIJING: China National Biotec Group (CNBG) said on Wednesday (Jul 1) it has completed construction of a new plant for coronavirus vaccines, ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

HDB resale prices rise marginally in Q2 amid Covid-19 outbreak: flash estimates[SINGAPORE] Housing Board (HDB) resale prices increased marginally in the second quarter of 2020 amid the Covid-19 break, compared with the first quarter of the year. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »

Upgrades and rebuilding of school campuses delayed by COVID-19SINGAPORE: Infrastructure projects for two secondary schools and four junior colleges will be deferred by one year due to a slowdown in the ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »